Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

Everolimus and Octreotide for Patients with Recurrent Meningioma: Results from the Phase II CEVOREM Trial.

Graillon T, Sanson M, Campello C, Idbaih A, Peyre M, Peyrière H, Basset N, Autran D, Roche C, Kalamarides M, Roche PH, Fuentes S, Tabouret E, Barrie M, Cohen A, Honoré S, Boucekine M, Baumstarck K, Figarella-Branger D, Barlier A, Dufour H, Chinot OL.

Clin Cancer Res. 2020 Feb 1;26(3):552-557. doi: 10.1158/1078-0432.CCR-19-2109. Epub 2020 Jan 22.

PMID:
31969329
2.

A genome-wide association study identifies susceptibility loci for primary central nervous system lymphoma at 6p25.3 and 3p22.1: a LOC network study.

Labreche K, Daniau M, Sud A, Law PJ, Royer-Perron L, Holroyd A, Broderick P, Went M, Benazra M, Ahle G, Soubeyran P, Taillandier L, Chinot OL, Casasnovas O, Bay JO, Jardin F, Oberic L, Fabbro M, Damaj G, Brion A, Mokhtari K, Philippe C, Sanson M, Houillier C, Soussain C, Hoang-Xuan K, Houlston RS, Alentorn A; LOC Network.

Neuro Oncol. 2019 May 17. pii: noz088. doi: 10.1093/neuonc/noz088. [Epub ahead of print]

PMID:
31102405
3.

MGMT Promoter Methylation Cutoff with Safety Margin for Selecting Glioblastoma Patients into Trials Omitting Temozolomide: A Pooled Analysis of Four Clinical Trials.

Hegi ME, Genbrugge E, Gorlia T, Stupp R, Gilbert MR, Chinot OL, Nabors LB, Jones G, Van Criekinge W, Straub J, Weller M.

Clin Cancer Res. 2019 Mar 15;25(6):1809-1816. doi: 10.1158/1078-0432.CCR-18-3181. Epub 2018 Dec 4.

PMID:
30514777
4.

Negative Survival Impact of High Radiation Doses to Neural Stem Cells Niches in an IDH-Wild-Type Glioblastoma Population.

Muracciole X, El-Amine W, Tabouret E, Boucekine M, Barlier A, Petrirena G, Harivony T, Solignac L, Chinot OL, Macagno N, Figarella-Branger D, Padovani L.

Front Oncol. 2018 Oct 4;8:426. doi: 10.3389/fonc.2018.00426. eCollection 2018.

5.

Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial.

van den Bent MJ, Klein M, Smits M, Reijneveld JC, French PJ, Clement P, de Vos FYF, Wick A, Mulholland PJ, Taphoorn MJB, Lewis J, Weller M, Chinot OL, Kros JM, de Heer I, Verschuere T, Coens C, Golfinopoulos V, Gorlia T, Idbaih A.

Lancet Oncol. 2018 Sep;19(9):1170-1179. doi: 10.1016/S1470-2045(18)30362-0. Epub 2018 Aug 13.

PMID:
30115593
6.

Associations of anticoagulant use with outcome in newly diagnosed glioblastoma.

Le Rhun E, Genbrugge E, Stupp R, Chinot OL, Nabors LB, Cloughesy T, Reardon DA, Wick W, Gorlia T, Weller M.

Eur J Cancer. 2018 Sep;101:95-104. doi: 10.1016/j.ejca.2018.06.029. Epub 2018 Jul 20.

PMID:
30036741
7.

Understanding the quality of life (QOL) issues in survivors of cancer: towards the development of an EORTC QOL cancer survivorship questionnaire.

van Leeuwen M, Husson O, Alberti P, Arraras JI, Chinot OL, Costantini A, Darlington AS, Dirven L, Eichler M, Hammerlid EB, Holzner B, Johnson CD, Kontogianni M, Kjær TK, Morag O, Nolte S, Nordin A, Pace A, Pinto M, Polz K, Ramage J, Reijneveld JC, Serpentini S, Tomaszewski KA, Vassiliou V, Verdonck-de Leeuw IM, Vistad I, Young TE, Aaronson NK, van de Poll-Franse LV; EORTC QLG.

Health Qual Life Outcomes. 2018 Jun 4;16(1):114. doi: 10.1186/s12955-018-0920-0.

8.

Temozolomide Plus Bevacizumab in Elderly Patients with Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial (ATAG).

Reyes-Botero G, Cartalat-Carel S, Chinot OL, Barrie M, Taillandier L, Beauchesne P, Catry-Thomas I, Barrière J, Guillamo JS, Fabbro M, Frappaz D, Benouaich-Amiel A, Le Rhun E, Campello C, Tennevet I, Ghiringhelli F, Tanguy ML, Mokhtari K, Honnorat J, Delattre JY.

Oncologist. 2018 May;23(5):524-e44. doi: 10.1634/theoncologist.2017-0689. Epub 2018 Feb 22.

9.

Plasma YKL-40 as a biomarker for bevacizumab efficacy in patients with newly diagnosed glioblastoma in the phase 3 randomized AVAglio trial.

Boisen MK, Holst CB, Consalvo N, Chinot OL, Johansen JS.

Oncotarget. 2017 Dec 4;9(6):6752-6762. doi: 10.18632/oncotarget.22886. eCollection 2018 Jan 23.

10.

Radiologic progression of glioblastoma under therapy-an exploratory analysis of AVAglio.

Nowosielski M, Ellingson BM, Chinot OL, Garcia J, Revil C, Radbruch A, Nishikawa R, Mason WP, Henriksson R, Saran F, Kickingereder P, Platten M, Sandmann T, Abrey LE, Cloughesy TF, Bendszus M, Wick W.

Neuro Oncol. 2018 Mar 27;20(4):557-566. doi: 10.1093/neuonc/nox162.

11.

Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study.

van den Bent MJ, Baumert B, Erridge SC, Vogelbaum MA, Nowak AK, Sanson M, Brandes AA, Clement PM, Baurain JF, Mason WP, Wheeler H, Chinot OL, Gill S, Griffin M, Brachman DG, Taal W, Rudà R, Weller M, McBain C, Reijneveld J, Enting RH, Weber DC, Lesimple T, Clenton S, Gijtenbeek A, Pascoe S, Herrlinger U, Hau P, Dhermain F, van Heuvel I, Stupp R, Aldape K, Jenkins RB, Dubbink HJ, Dinjens WNM, Wesseling P, Nuyens S, Golfinopoulos V, Gorlia T, Wick W, Kros JM.

Lancet. 2017 Oct 7;390(10103):1645-1653. doi: 10.1016/S0140-6736(17)31442-3. Epub 2017 Aug 8. Erratum in: Lancet. 2017 Oct 7;390(10103):1644.

12.

Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O6-Methylguanine-DNA Methyltransferase Biomarker Analyses.

Cloughesy T, Finocchiaro G, Belda-Iniesta C, Recht L, Brandes AA, Pineda E, Mikkelsen T, Chinot OL, Balana C, Macdonald DR, Westphal M, Hopkins K, Weller M, Bais C, Sandmann T, Bruey JM, Koeppen H, Liu B, Verret W, Phan SC, Shames DS.

J Clin Oncol. 2017 Jan 20;35(3):343-351. doi: 10.1200/JCO.2015.64.7685. Epub 2016 Dec 5.

PMID:
27918718
13.

Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastoma.

Wick W, Chinot OL, Bendszus M, Mason W, Henriksson R, Saran F, Nishikawa R, Revil C, Kerloeguen Y, Cloughesy T.

Neuro Oncol. 2016 Oct;18(10):1434-41. doi: 10.1093/neuonc/now091. Epub 2016 Aug 11.

14.

Upfront bevacizumab may extend survival for glioblastoma patients who do not receive second-line therapy: an exploratory analysis of AVAglio.

Chinot OL, Nishikawa R, Mason W, Henriksson R, Saran F, Cloughesy T, Garcia J, Revil C, Abrey L, Wick W.

Neuro Oncol. 2016 Sep;18(9):1313-8. doi: 10.1093/neuonc/now046. Epub 2016 Mar 22.

15.

Reply to T.J. Kruser et al.

Chinot OL, Taphoorn MJ, Bais C, Bourgon R, Phillips HS, Abrey LE, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Cloughesy T.

J Clin Oncol. 2016 Apr 10;34(11):1282-3. doi: 10.1200/JCO.2015.65.2438. Epub 2016 Feb 16. No abstract available.

PMID:
26884575
16.

Bevacizumab, temozolomide, and radiotherapy for newly diagnosed glioblastoma: comprehensive safety results during and after first-line therapy.

Saran F, Chinot OL, Henriksson R, Mason W, Wick W, Cloughesy T, Dhar S, Pozzi E, Garcia J, Nishikawa R.

Neuro Oncol. 2016 Jul;18(7):991-1001. doi: 10.1093/neuonc/nov300. Epub 2016 Jan 24.

17.

Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial.

Sandmann T, Bourgon R, Garcia J, Li C, Cloughesy T, Chinot OL, Wick W, Nishikawa R, Mason W, Henriksson R, Saran F, Lai A, Moore N, Kharbanda S, Peale F, Hegde P, Abrey LE, Phillips HS, Bais C.

J Clin Oncol. 2015 Sep 1;33(25):2735-44. doi: 10.1200/JCO.2015.61.5005. Epub 2015 Jun 29. Erratum in: J Clin Oncol. 2016 Sep 1;34(25):3113.

18.

Health-Related Quality of Life in a Randomized Phase III Study of Bevacizumab, Temozolomide, and Radiotherapy in Newly Diagnosed Glioblastoma.

Taphoorn MJ, Henriksson R, Bottomley A, Cloughesy T, Wick W, Mason WP, Saran F, Nishikawa R, Hilton M, Theodore-Oklota C, Ravelo A, Chinot OL.

J Clin Oncol. 2015 Jul 1;33(19):2166-75. doi: 10.1200/JCO.2014.60.3217. Epub 2015 May 26.

PMID:
26014298
19.

Phase 1 dose-escalation study of the antiplacental growth factor monoclonal antibody RO5323441 combined with bevacizumab in patients with recurrent glioblastoma.

Lassen U, Chinot OL, McBain C, Mau-Sørensen M, Larsen VA, Barrie M, Roth P, Krieter O, Wang K, Habben K, Tessier J, Lahr A, Weller M.

Neuro Oncol. 2015 Jul;17(7):1007-15. doi: 10.1093/neuonc/nov019. Epub 2015 Feb 9.

20.

The future of antiangiogenic treatment in glioblastoma.

Chinot OL, Reardon DA.

Curr Opin Neurol. 2014 Dec;27(6):675-82. doi: 10.1097/WCO.0000000000000142. Review.

PMID:
25313693
21.

Cilengitide in glioblastoma: when did it fail?

Chinot OL.

Lancet Oncol. 2014 Sep;15(10):1044-5. doi: 10.1016/S1470-2045(14)70403-6. Epub 2014 Aug 19. No abstract available.

PMID:
25163907
22.

Bevacizumab for newly diagnosed glioblastoma.

Chinot OL, Wick W, Cloughesy T.

N Engl J Med. 2014 May 22;370(21):2049. doi: 10.1056/NEJMc1403303. No abstract available.

PMID:
24860870
23.

Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.

Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Carpentier AF, Hoang-Xuan K, Kavan P, Cernea D, Brandes AA, Hilton M, Abrey L, Cloughesy T.

N Engl J Med. 2014 Feb 20;370(8):709-22. doi: 10.1056/NEJMoa1308345.

24.

Response assessment criteria for glioblastoma: practical adaptation and implementation in clinical trials of antiangiogenic therapy.

Chinot OL, Macdonald DR, Abrey LE, Zahlmann G, Kerloëguen Y, Cloughesy TF.

Curr Neurol Neurosci Rep. 2013 May;13(5):347. doi: 10.1007/s11910-013-0347-2. Review.

25.

Bevacizumab-based therapy in relapsed glioblastoma: rationale and clinical experience to date.

Chinot OL.

Expert Rev Anticancer Ther. 2012 Nov;12(11):1413-27. doi: 10.1586/era.12.128. Review.

PMID:
23249106
26.

AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme.

Chinot OL, de La Motte Rouge T, Moore N, Zeaiter A, Das A, Phillips H, Modrusan Z, Cloughesy T.

Adv Ther. 2011 Apr;28(4):334-40. doi: 10.1007/s12325-011-0007-3. Epub 2011 Mar 14.

PMID:
21432029
27.

Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide.

Chinot OL, Barrié M, Fuentes S, Eudes N, Lancelot S, Metellus P, Muracciole X, Braguer D, Ouafik L, Martin PM, Dufour H, Figarella-Branger D.

J Clin Oncol. 2007 Apr 20;25(12):1470-5.

PMID:
17442989
28.

[Cerebral metastases].

Chinot OL.

Rev Prat. 2006 Oct 31;56(16):1799-804. Review. French.

PMID:
17315506
29.

Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in an elderly populations.

Chinot OL, Barrie M, Frauger E, Dufour H, Figarella-Branger D, Palmari J, Braguer D, Hoang-Xuan K, Moktari K, Peragut JC, Martin PM, Grisoli F.

Cancer. 2004 May 15;100(10):2208-14.

30.

Should radiotherapy be standard therapy for brain tumors in the elderly? Cons.

Chinot OL.

Semin Oncol. 2003 Dec;30(6 Suppl 19):68-71. Review.

PMID:
14765390
31.

Treatment of primary central nervous system lymphoma in the elderly.

Hoang-Xuan K, Chinot OL, Taillandier L.

Semin Oncol. 2003 Dec;30(6 Suppl 19):53-7. Review.

PMID:
14765387
32.

Recent developments in the molecular characterization and treatment of oligodendroglial tumors.

van den Bent M, Chinot OL, Cairncross JG.

Neuro Oncol. 2003 Apr;5(2):128-38. Review.

33.

Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy.

Chinot OL, Honore S, Dufour H, Barrie M, Figarella-Branger D, Muracciole X, Braguer D, Martin PM, Grisoli F.

J Clin Oncol. 2001 May 1;19(9):2449-55.

PMID:
11331324

Supplemental Content

Loading ...
Support Center